Wall Street brokerages predict that Applied DNA Sciences, Inc. (NASDAQ:APDN) will post $2.31 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Applied DNA Sciences’ earnings, with the lowest sales estimate coming in at $1.87 million and the highest estimate coming in at $2.75 million. Applied DNA Sciences posted sales of $310,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 645.2%. The business is expected to announce its next quarterly earnings report on Thursday, December 16th.
According to Zacks, analysts expect that Applied DNA Sciences will report full year sales of $8.30 million for the current year, with estimates ranging from $7.86 million to $8.74 million. For the next fiscal year, analysts expect that the company will report sales of $19.64 million, with estimates ranging from $19.17 million to $20.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Applied DNA Sciences.
Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Wednesday, August 11th. The technology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.20). The company had revenue of $1.70 million during the quarter, compared to analyst estimates of $3.44 million. Applied DNA Sciences had a negative return on equity of 116.69% and a negative net margin of 220.18%.
Shares of NASDAQ APDN traded up $0.28 during mid-day trading on Wednesday, reaching $5.68. The company had a trading volume of 6,421 shares, compared to its average volume of 973,505. The stock has a market cap of $42.52 million, a PE ratio of -2.39 and a beta of 1.01. The company has a 50-day moving average price of $5.80 and a two-hundred day moving average price of $6.38. Applied DNA Sciences has a 1-year low of $4.95 and a 1-year high of $13.64.
Several institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new stake in Applied DNA Sciences during the second quarter valued at $85,000. Dimensional Fund Advisors LP acquired a new stake in Applied DNA Sciences during the second quarter valued at $100,000. Orion Portfolio Solutions LLC boosted its position in Applied DNA Sciences by 34.1% during the second quarter. Orion Portfolio Solutions LLC now owns 18,719 shares of the technology company’s stock valued at $127,000 after purchasing an additional 4,756 shares during the last quarter. Premier Asset Management LLC acquired a new stake in Applied DNA Sciences during the first quarter valued at $144,000. Finally, Virtu Financial LLC acquired a new stake in Applied DNA Sciences during the first quarter valued at $195,000. 7.03% of the stock is owned by institutional investors and hedge funds.
Applied DNA Sciences Company Profile
Applied DNA Sciences, Inc engages in the provision of security solutions. The firm offers molecular-based technology solutions and services that can help protect products, brands, supply chains, and intellectual property of companies, governments, and consumers from theft, counterfeiting, fraud, and diversion.
Read More: Bollinger Bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.